Richard Ceska

Richard Ceska

Auto-generated profile, based on publicly available information

Richard Ceska

Center of Preventive Cardiology, 3rd Dept. Internal Med., 1st School of Medicine and University Hospital, Charles University, Prague, Czech Republic

Research Focus & Metrics

Academic Career Length

40Years (1987-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 May 2014 in New England Journal of Medicine
Verified
Journal Article
Open access
PDF file
DBDirk J. Blom
Dirk J. Blom
THTomas Hala
Tomas Hala
MBMichael Bolognese
Michael Bolognese
MLMichael J. Lillestol
Michael J. Lillestol
PTPhillip D. Toth
Phillip D. Toth
ESEvan A. Stein
Evan A. Stein
Evolocumab, a monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9), significantly reduced low-density lipoprotein (LDL) cholesterol levels in phase 2 studies. We conducted a phase 3 trial to evaluate the safety and efficacy of 52 weeks of treatment with evolocumab. We stratified patients with hyperlipidemia according to the risk categories outlined by the Adult Treatment Panel III of the National Cholesterol Education Program. On the basis of this classification, patients were started on background lipid-lowering therapy with diet alone or diet plus atorvastatin at a dose of 10 mg daily, atorvastatin at a dose of 80 mg daily, or atorvastatin at a dose of 80 mg daily plus ezetimibe at a dose of 10 mg daily, for a run-in period of 4 to 12 weeks. Patients with an LDL cholesterol level of 75 mg per deciliter (1.9 mmol per liter) or higher were then randomly assigned in a 2:1 ratio to receive either evolocumab (420 mg) or placebo every 4 weeks. The primary end point was the percent change from baseline in LDL cholesterol, as measured by means of ultracentrifugation, at week 52. Among the 901 patients included in the primary analysis, the overall least-squares mean (±SE) reduction in LDL cholesterol from baseline in the evolocumab group, taking into account the change in the placebo group, was 57.0±2.1% (P<0.001). The mean reduction was 55.7±4.2% among patients who underwent background therapy with diet alone, 61.6±2.6% among those who received 10 mg of atorvastatin, 56.8±5.3% among those who received 80 mg of atorvastatin, and 48.5±5.2% among those who received a combination of 80 mg of atorvastatin and 10 mg of ezetimibe (P<0.001 for all comparisons). Evolocumab treatment also significantly reduced levels of apolipoprotein B, non–high-density lipoprotein cholesterol, lipoprotein(a), and triglycerides. The most common adverse events were nasopharyngitis, upper respiratory tract infection, influenza, and back pain. At 52 weeks, evolocumab added to diet alone, to low-dose atorvastatin, or to high-dose atorvastatin with or without ezetimibe significantly reduced LDL cholesterol levels in patients with a range of cardiovascular risks. (Funded by Amgen; DESCARTES ClinicalTrials.gov number, NCT01516879.)

19 April 2016 in JAMA
Verified
Journal Article
Open access
PDF file
SNSteven E. Nissen
Steven E. Nissen
ESErik Stroes
Erik Stroes
RDRicardo E. Dent-Acosta
Ricardo E. Dent-Acosta
RRRobert S. Rosenson
Robert S. Rosenson
SLSam J. Lehman
Sam J. Lehman
ESEvan A. Stein
Evan A. Stein
Quiz Ref ID Administration of HMG-CoA reductase inhibitors (statins) to reduce levels of low-density lipoprotein cholesterol (LDL-C) represents an essential component of contemporary strategies to reduce morbidity and mortality from atherosclerotic vascular disease.1 However, a significant proportion of patients with clinical indications for statin treatment report inability to tolerate evidence-based doses, most commonly because of muscle-related adverse effects.2 These patients typically report muscle pain or weakness when treatment is initiated or dosage increased and relief when the drug is discontinued or the dosage reduced. Although some patients with statin-associated muscle symptoms experience marked elevation in serum creatine kinase (CK) levels, most do not. Accordingly, diagnosis of this disorder remains largely subjective, based on the presence of patient-reported symptoms.3 The incidence of similar symptoms in placebo-treated patients has resulted in skepticism about the true incidence of statin intolerance.

1 January 2015 in Archives of Medical Science
Verified
Journal Article
Open access
Maciej BanachMaciej Banach
Maciej Banach
MANFREDI RIZZOMANFREDI RIZZO
MANFREDI RIZZO
PTPeter P. Toth
Peter P. Toth
MFMichel Farnier
Michel Farnier
MDMichael H. Davidson
Michael H. Davidson
DMDimitri P. Mikhailidis
Dimitri P. Mikhailidis
Statins are one of the most commonly prescribed drugs in clinical practice. They are usually well tolerated and effectively prevent cardiovascular events. Most adverse effects associated with statin therapy are muscle-related. The recent statement of the European Atherosclerosis Society (EAS) has...

1 November 2008 in The American Journal of Cardiology
Verified
Journal Article
Closed access
JFJean-Charles Fruchart
Jean-Charles Fruchart
FSFrank Sacks
Frank Sacks
MHMichel P. Hermans
Michel P. Hermans
GAGerd Assmann
Gerd Assmann
WBW. Virgil Brown
W. Virgil Brown
PZPaul Zimmet
Paul Zimmet

1 September 2015 in European Heart Journal
Verified
Journal Article
Open access
PDF file
JKJohn Jacob Pieter Kastelein
John Jacob Pieter Kastelein
HGHenry N. Ginsberg
Henry N. Ginsberg
GLGisle Langslet
Gisle Langslet
GHG. Kees Hovingh
G. Kees Hovingh
RCRichard Ceska
Richard Ceska
MFMichel Farnier
Michel Farnier
To assess long-term (78 weeks) alirocumab treatment in patients with heterozygous familial hypercholesterolaemia (HeFH) and inadequate LDL-C control on maximally tolerated lipid-lowering therapy (LLT). In two randomized, double-blind studies (ODYSSEY FH I, n = 486; FH II, n = 249), patients were randomized 2 : 1 to alirocumab 75 mg or placebo every 2 weeks (Q2W). Alirocumab dose was increased at Week 12 to 150 mg Q2W if Week 8 LDL-C was ≥1.8 mmol/L (70 mg/dL). Primary endpoint (both studies) was percentage change in calculated LDL-C from baseline to Week 24. Mean LDL-C levels decreased from 3.7 mmol/L (144.7 mg/dL) at baseline to 1.8 mmol/L (71.3 mg/dL; −57.9% vs. placebo) at Week 24 in patients randomized to alirocumab in FH I and from 3.5 mmol/L (134.6 mg/dL) to 1.8 mmol/L (67.7 mg/dL; −51.4% vs. placebo) in FH II (P < 0.0001). These reductions were maintained through Week 78. LDL-C <1.8 mmol/L (regardless of cardiovascular risk) was achieved at Week 24 by 59.8 and 68.2% of alirocumab-treated patients in FH I and FH II, respectively. Adverse events resulted in discontinuation in 3.4% of alirocumab-treated patients in FH I (vs. 6.1% placebo) and 3.6% (vs. 1.2%) in FH II. Rate of injection site reactions in alirocumab-treated patients was 12.4% in FH I and 11.4% in FH II (vs. 11.0 and 7.4% with placebo). In patients with HeFH and inadequate LDL-C control at baseline despite maximally tolerated statin ± other LLT, alirocumab treatment resulted in significant LDL-C lowering and greater achievement of LDL-C target levels and was well tolerated. Cinicaltrials.gov (identifiers: NCT01623115; NCT01709500).

15 November 2000 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
SCSusanne M. Clee
Susanne M. Clee
JKJohn J.P. Kastelein
John J.P. Kastelein
MDMarjel van Dam
Marjel van Dam
MMMichel Marcil
Michel Marcil
KRKirsten Roomp
Kirsten Roomp
MHMichael R. Hayden
Michael R. Hayden
We and others have recently identified mutations in the ABCA1 gene as the underlying cause of Tangier disease (TD) and of a dominantly inherited form of familial hypoalphalipoproteinemia (FHA) associated with reduced cholesterol efflux. We have now identified 13 ABCA1 mutations in 11 families (five TD, six FHA) and have examined the phenotypes of 77 individuals heterozygous for mutations in the ABCA1 gene. ABCA1 heterozygotes have decreased HDL cholesterol (HDL-C) and increased triglycerides. Age is an important modifier of the phenotype in heterozygotes, with a higher proportion of heterozygotes aged 30–70 years having HDL-C greater than the fifth percentile for age and sex compared with carriers less than 30 years of age. Levels of cholesterol efflux are highly correlated with HDL-C levels, accounting for 82% of its variation. Each 8% change in ABCA1-mediated efflux is predicted to be associated with a 0.1 mmol/l change in HDL-C. ABCA1 heterozygotes display a greater than threefold increase in the frequency of coronary artery disease (CAD), with earlier onset than unaffected family members. CAD is more frequent in those heterozygotes with lower cholesterol efflux values. These data provide direct evidence that impairment of cholesterol efflux and consequently reverse cholesterol transport is associated with reduced plasma HDL-C levels and increased risk of CAD.